Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-05-11
Based on 414 first isolates · GER · Febrile UTI / pyelonephritis · 2024-05-12 → 2025-05-11
Geriatrics
Per-organism detail: GER urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
meropenem 84 % (80 %–87 %)
Carbapenem: reserve for ESBL / critically ill patients.
Not covered: Enterococcus faecalis (9 %), Staphylococcus aureus (5 %), Staphylococcus saprophyticus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
79 %
n = 28
nitrofurantoin NIT
trend · Escherichia coli not for this site
83 %
86 %
n = 28
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
75 %
n = 28
mecillinam MEC
trend · Escherichia coli not for this site
76 %
71 %
n = 28
ceftriaxone CRO
trend · Escherichia coli
76 %
71 %
n = 28
ciprofloxacin CIP
trend · Escherichia coli
76 %
68 %
n = 28
71 %
68 %
n = 28
trimethoprim TMP
trend · Escherichia coli not for this site
70 %
89 %
n = 28
49 %
36 %
n = 28
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
18 %
n = 28
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
5 %
18 %
n = 28
4 %
4 %
n = 28

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
10 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Staphylococcus aureus
5 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.